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Objective: Some evidence suggests that heart rate variability (HRV) biofeedback might be an 
effective way to treat anxiety and stress symptoms. To examine the effect of HRV biofeedback 
on symptoms of anxiety and stress, we conducted a meta-analysis of studies extracted from 
PubMed, PsycINFO, and the Cochrane Library. 
Methods: The search identified 24 studies totaling 484 participants who received HRV 
biofeedback training for stress and anxiety. We conducted a random-effects meta-analysis. 
Results: The pre-post within-group effect size (Hedges’ g) was 0.81. The between-groups 
analysis comparing biofeedback to a control condition yielded Hedges’ g = 0.83. Moderator 
analyses revealed that treatment efficacy was not moderated by study year, risk of study bias, 
percentage of females, number of sessions, or presence of an anxiety disorder.  
Conclusions: HRV biofeedback training is associated with a large reduction in self-reported 
stress and anxiety. Although more well-controlled studies are needed, this intervention offers a 
promising approach for treating stress and anxiety with wearable devices.  
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Introduction 
Individuals with elevated levels of anxiety and stress often report using complementary 
and alternative therapies (Kessler et al. 2001). One of these interventions, heart rate variability 
(HRV) biofeedback training, has received increasing attention as a potential treatment for a 
variety of disorders, including anxiety and stress (Lehrer & Gevirtz 2014).  
It has been suggested that stress and negative affect can be improved through adaptive 
emotion regulation (Gross 2002; Hofmann 2014), which is a form of self-regulation that is 
expressed through certain physiological measures, especially HRV. HRV is a measure of cardiac 
vagal tone that can be quantified through the application of spectral analysis of the beat-to-beat 
(R-R) intervals (e.g., Porges, 2007). More specifically, this measure can be derived by integrating 
over the high frequency (HF) spectral component of R–R intervals at 0.15–0.40 Hz (in ms2; see 
Berntson et al., 1997; Camm et al., 1996). This high-frequency peak is thought to reflect the 
magnitude of respiratory sinus arrhythmia without requiring the assessment of respiratory rate. 
Low HRV has been associated with a number of psychopathological states, including anxiety 
(e.g., Friedman, 2007; Hofmann, Moscovitch, Litz, Kim, Davis, & Pizzagalli, 2005).  
High resting HRV has been shown to predict self-regulatory strength and reduced 
negative emotion during acute stress (Khodik 2013). Some research indicated that HRV might be 
an index of self-regulatory strength (Segerstrom & Nes 2007). In addition to cultivating enhanced 
self-awareness (Kim et al. 2015), HRV biofeedback might enable individuals to regulate their 
physiological functioning for example through breathing training, which thereby contributes to 
relaxation (for review see Khazan 2013). This approach is in line with mindfulness meditation 
exercises (Lehrer & Gevirtz 2014) and may enhance self-regulation capacities (Vago & 
Silbersweig 2012). Indeed, several studies suggest that HRV biofeedback may be an effective 
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treatment for generalized anxiety disorder and post-traumatic stress disorder (i.e., Zucker et al. 
2009; Kemp et al. 2012).  
A number of qualitative reviews (Futterman & Shapiro 1986; Gevirtz 2013; Tabachnick 
2015) supported the notion that HRV biofeedback is effective for improving stress and anxiety. 
However, to our knowledge, there is no quantitative (meta-analytic) review examining the 
efficacy of this intervention. We hypothesized that HRV biofeedback is an effective intervention 
for anxiety and stress. Although biofeedback has a relatively long history, it is not a commonly-
used intervention, partly because of the cost of earlier devices. If HRV biofeedback shows 
promise, then this might provide impetus for the further development of wearable devices, such 
as fitness trackers and smartwatches. 
Methods 
Identification and selection of studies 
To identify eligible studies, a literature search was conducted in PubMed, PsycINFO and 
Cochrane Library databases. The following search terms were used: (heart rate variability 
biofeedback OR HRVB OR respiratory sinus arrhythmia biofeedback OR RSA biofeedback OR 
resonance frequency feedback OR RFF OR biofeedback*) AND (Anxiety OR anxiety disorders 
OR anxiety disorder OR anxious OR panic OR panic disorder OR agoraphobia OR social 
phobia OR social anxiety OR social anxiety disorder OR sad OR generalized anxiety OR gad OR 
general anxiety disorder OR obsessive compulsive OR obsessive-compulsive OR ocd OR 
obsessive compulsive disorder OR obsessive-compulsive disorder OR specific phobia OR simple 
phobia OR phob* OR post-traumatic stress OR posttraumatic stress OR ptsd OR acute stress 
OR posttraumatic stress OR post-traumatic stress disorder OR posttraumatic stress disorder OR 
post traumatic stress disorder OR asd).  
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The initial search produced 2,297 results, with 1,801 publications remaining after 
duplicates were excluded (see Figure 1). Furthermore, we examined the references of the eligible 
papers. No language restrictions were applied.  
 Studies were included in the present meta-analysis if (1) at least one treatment condition 
was HRV biofeedback; (2) a psychometrically adequate measure of self-reported stress or anxiety 
was used; (3) the sample included individuals 18 years or older; and (4) sufficient descriptive 
statistics were provided to compute effect sizes.  
 Studies were excluded if (1) the paper was a review, a meta-analysis, a survey, a manual, 
or a conference abstract; if (2) they used other methods of biofeedback like electromyography 
(EMG) or electroencephalography (EEG); or if (3) HRV biofeedback was combined with another 
active treatment (e.g., cognitive behavioral therapy, mindfulness meditation, progressive muscle 
relaxation, motivational interviewing). However, studies were permitted if they combined HRV 
biofeedback with some aspects of common factors (e.g., initial education about biofeedback). If a 
study met all inclusion criteria, but the published manuscript lacked the necessary data to 
calculate an effect size, we emailed the corresponding author to request the data to conduct the 
analyses.  
 For each selected study, the authors extracted data on self-reported stress and anxiety 
measures at pre- and post-treatment for the HRV Biofeedback intervention, as well as data from 
control and comparison conditions if included. In addition, we extracted data for a number of 
sample and study characteristics, including sample size, treatment duration, gender, clinical status 
of the participants, and the study year.  
Quality assessment 
For assessing the study quality, we used the Cochrane Handbook for assessing the risk of 
bias (Higgins et al. 2011). Using this tool, each study was classified as having a high, low or 
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unclear level of bias risk for a number of domains using pre-specified criteria. The domains used 
in this assessment were: (1) Sequence Generation, which assesses whether all participants are 
adequately randomized to the different treatment conditions; (2) Allocation Concealment, which 
assesses whether investigators and participants are blind for the treatment assignment prior to 
randomization; (3) Incomplete Outcome Data, which assesses whether the studies reported 
missing data and whether appropriate methods were used for calculation (e.g., multiple 
imputation, full-information maximum likelihood estimation, etc.); and (4) Selective Outcome 
Reporting, which assesses whether all measurements of interest were adequately and completely 
reported. For each study a total bias assessment was created. Following the recommendations 
from the Cochrane guidelines, studies were rated as ‘unclear risk’, when at least one of the four 
categories showed an ‘unclear’ rating. If one of the four categories were rated with a ‘high’ risk, 
the study received a ‘high risk’ overall rating. ‘Low risk’ studies had to be rated as ‘low’ risk in 
all four categories.  
Meta-analysis 
We collected data on study characteristics including study year, number of biofeedback 
sessions, percentage of female participants, clinical diagnosis of an anxiety disorder, and risk of 
study bias. 
We estimated the effect size by using Hedges’ g, which corrects for parameter bias due to 
small sample size (Rosenthal 1991). Both within and between pre-post effect sizes were 
calculated. To compute Hedges’ g, we extracted means and standard deviations, as well as 
information from significance tests (e.g., t, F) (Rosenthal 1991). The pooled effect sizes were 
estimated using random effects models, which assume significant heterogeneity of the included 
studies. Following Rosenthal (1991), we estimated the pre-post correlation to be r = .70. All 
analyses were completed with Comprehensive Meta-Analysis (Borenstein & Rothstein 2014). 
7 
The magnitude of Hedges’ g may be interpreted using Cohen’s (1988) convention as small (0.2), 
medium (0.5), and large (0.8). 
To investigate the influence of potential moderator variables on the effect of HRV 
biofeedback, we employed the between-group heterogeneity statistic (QB) recommended by 
Hedges and Olkin (1985) and meta-regression procedures for categorical and continuous 
moderators, respectively. Moderators of interest included both treatment characteristics (i.e., 
study year, number of biofeedback sessions) and sample characteristics (i.e., percentage of 
females per study, clinical diagnosis of an anxiety disorder, and risk of study bias).  
To examine the presence of publication bias, we inspected the funnel plot. In addition, we 
used the fail-safe N method to determine the number of additional studies with a null result 
needed to reduce the overall effect size to non-significance (Rosenthal 1991a). If the fail-safe N 
exceeds 5 multiplied by K (i.e., the number of studies in the meta-analysis) + 10, then the results 
may be considered statistically robust. Although a commonly used method, the fail-safe N 
approach tends to overestimate the number of studies needed to make moderate effect sizes non-
significant. Therefore, we also examined the funnel plot to evaluate symmetry relative to the 
mean effect size, with greater symmetry corresponding to decreased likelihood of publication 
bias. To complement the funnel plot inspection, the trim and fill method (Duval & Tweedie 2000) 
was utilized to determine the nature of potential publication bias and to compute an imputed 
effect size that accounts for it. Finally, we examined Egger's regression intercept to determine 
whether results might be biased as a consequence of study number. 
Results 
Study Characteristics 
A total of 232 articles with HRV biofeedback treatment were found. Of those, 188 articles 
were excluded because they did not satisfy the inclusion criteria. Eight articles were excluded 
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because of insufficient data. A total of 24 studies totaling 484 subjects that met inclusion criteria 
were included in this meta-analysis (Figure 1). Characteristics of these 24 studies are described in 
Table 1. Subjects were recruited from both community (n = 14 studies) and clinical settings (n = 
10 studies). The number of sessions varied between 1 and 50. Participants were told to train at 
home with a portable biofeedback device or were treated with a fixed number of sessions from a 
biofeedback trainer. There were 13 studies that included a comparison group (i.e., 6 were waitlist, 
1 was standard care, 2 were treatment as usual, 1 was a daily thought record, 1 was progressive 
muscle relaxation, and 2 were sham biofeedback).  
We observed heterogeneity in the quality ratings of the studies. In only 2 studies, 
allocation concealment to conditions was conducted by an independent party. In 15 studies, the 
randomization procedures were not adequately described and had an unclear risk. In 3 studies, 
improper randomization procedures were used. In 20 studies, the authors did not report the 
concealment of random allocation to respondents. In one study, allocation concealment 
procedures were explicitly described. One study had a high risk in allocation concealment. The 
handling of missing data was adequately addressed in 2 studies. Risk of bias due to missing data 
remained unclear for 13 studies, and 9 studies employed procedures that did not adequately 
address missing data. In all studies, the measurements of interest were adequately and completely 
reported.   
Efficacy of Biofeedback 
Pre-post within-group effects. The random effects meta-analysis yielded an overall 
within-group effect size on anxiety of Hedges’ g = 0.81 (95% CI: 0.55-1.06, z = 6.23, p < .001). 
The fail-safe N analysis for the within-group effect size was robust with N = 1,858 (z = 17.35). 
Inspection of the funnel plot revealed a distribution of effect sizes concentrated to the left of the 
mean effect size, which indicates a decreased likelihood of publication bias from small studies 
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with disproportionately large effect sizes (Figure 2). The Trim and Fill method was used to 
further examine potential bias as determined by the funnel plot. This analysis showed that 0 
studies would need to fall to the left of the mean (i.e., have an effect size smaller than the mean) 
and 3 studies would need to fall to the right of the mean (i.e., have an effect size larger than the 
mean) to make the plot symmetrical, suggesting that the computed effect size is a conservative 
estimate. The random-effects model for the new imputed mean effect size revealed a Hedges’ g = 
0.88 (95% CI: 0.81-0.96). Furthermore, the Egger’s regression intercept was not significant 
(intercept = 0.64, p = 0.74), suggesting that the parameter estimates were not influenced by the 
number of studies. 
 Pre-post between-group effect sizes. For the between-groups analysis comparing 
biofeedback to another condition (i.e., standard care, waitlist, daily record, progressive muscle 
relaxation, treatment as usual, meditation-based, or sham biofeedback), the random-effects 
analyses yielded an overall effect size of Hedges’ g = 0.83 (95% CI: 0.34-1.33, z = 3.34, p < 
.001). The fail-safe N for this analysis was robust with N = 243 (z = 8.69). The Trim and Fill 
analysis revealed that no studies would need to fall to the right or left of the mean to make the 
plot symmetrical, suggesting a conservative effect size estimate. The random-effects model for 
the new imputed mean effect size revealed a Hedges’ g = 0.83 (95% CI: 0.34-1.33). Furthermore, 
the Egger’s regression intercept was not significant (intercept = -1.72, p = 0.35). 
Moderator Analyses 
Moderator analyses were conducted to determine whether within-group treatment efficacy 
varied as a function of participant and study characteristics. Specifically, the following five 
moderator variables were examined: study year, number of biofeedback sessions, percentage of 
females per study, clinical diagnosis of an anxiety disorder, and risk of study bias.  
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The results suggested that the effect of risk of study bias on treatment efficacy was not 
statistically significant (QB = 0.12, df = 1, p = 0.73). Because only one study exhibited low risk of 
study bias, this moderation analysis was conducted with uncertain and high risk studies. Effect 
sizes were not significantly related to study year (B = 0.03, SE = 0.04, p = 0.48), percentage of 
females (B = -0.004, SE = 0.004, p =0.30), or number of sessions (B = -0.01, SE = 0.01, p = 0.21). 
The efficacy of HRV biofeedback on trait anxiety was not significantly different from that on 
state anxiety (QB = 2.92, df = 1, p = 0.09). Furthermore, treatment efficacy was not significantly 
related to the presence of an anxiety disorder (QB = 0.36, df = 1, p = 0.55).  
Discussion  
The results of this meta-analysis support the findings of earlier qualitative reviews (i.e. 
Futterman & Shapiro 1986; Gevirtz 2013; Tabachnick 2015), suggesting that HRV biofeedback 
is an effective treatment for anxiety. The within-group analysis revealed an effect size of Hedges’ 
g = 0.81, which was robust with a low likelihood of a publication bias. For the between-group 
analysis comparing HRV biofeedback to a comparison condition, the random-effects analyses 
yielded an overall effect size of Hedges’ g = 0.83. These results suggest that HRV biofeedback is 
a beneficial treatment for people with anxiety and stress.  
The moderator analyses revealed that treatment efficacy was not significantly related to 
study year, risk of study bias, percentage of females, number of sessions, outcome measure (i.e., 
trait vs. state anxiety), or presence of an anxiety disorder. It could be the case that the efficacy of 
HRV biofeedback is robust across a variety of treatment conditions and patient characteristics; 
however, it is impossible for the current meta-analysis to definitively address this question 
because a lack of statistical significance cannot be interpreted as evidence in favor of a null-
hypothesis. It will be important for future research to identify whether certain patient 
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characteristics predict differential treatment response to HRV biofeedback, which is consistent 
with precision medicine.  
Although there is good evidence to suggest that this intervention appears to be effective 
for anxiety and stress, the true size of the effect can only be determined after more rigorous 
clinical trials are completed in the future. In addition, several other limitations should be noted. 
First, although our meta-analysis included a relatively large number of studies, there were few 
studies with a clinical population. Because most of the studies did not report on specific anxiety 
disorder diagnoses, we were not able to calculate meaningful sub-analyses to examine whether 
HRV biofeedback is particularly effective for any specific anxiety disorder (and why). Second, 
due to the lack of studies with follow-up analyses, the long-term efficacy of HRV biofeedback 
remains uncertain. Third, prior research has suggested that outcome measure format (i.e., 
clinician rated vs. self-report) can influence effect size estimates (Cuijpers et al., 2010). All the 
outcome measures of the studies in the current meta-analysis were self-report, which may bias 
effect size estimates. Fourth, it could be the case that non-specific factors (e.g., patient 
expectancies, patient-therapist interactions, etc.) contributed to the effect sizes of HRV 
biofeedback. To better determine the efficacy of this intervention, adequate comparison 
conditions need to be developed to examine the mechanism of HRV biofeedback. Fifth, the 
included studies did not provide adequate detail to quantify the amount of time with therapists. 
Thus, we were not able to include this as a moderator. Sixth, it is difficult to account for the lack 
of moderator effect for number of sessions, which may raise some concern with regard to the 
assumed mechanism of the intervention. The absence of a dose-response relationship in HRV 
biofeedback has also been observed in individual studies (Zucker et al., 2009). Finally, the 
studies included in the current meta-analysis varied in the biofeedback protocols, which 
introduced a methodological confound. In the current study, the number of studies using any 
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given protocol was small, which precluded moderator analyses to examine differences in efficacy 
across separate biofeedback protocols.  
 Despite these limitations, the results suggest that HRV biofeedback is a highly promising 
intervention for reducing anxiety and stress. The overall results could provide a compelling 
rationale to examine HRV biofeedback as an adjunct intervention in combination with other 
empirically supported treatments (e.g., CBT). This intervention is becoming increasingly more 
attractive as a treatment aid with the rapid improvements and affordability of wearable devices 
(such as fitness trackers and smartwatches). 
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Table 1. Characteristics of randomized controlled studies examining the effect of HRV Biofeedback on self-reported stress and anxiety 
symptoms 
Study Country Mean age 
of sample  
Population Sample 
size (n) 
Percent of 
female 
Instrument Number of 
sessions 
Type of symptom Risk of study bias  
         R A I S T 
Beckham et al. 
(2013)  
USA 31 clinical 14 100 STAI-S 2 perinatal 
depression 
1 1 1 2 1 
Browne (2001) USA 39  clinical 10 50 DSP 10 Stress 
symptoms 
2 2 1 2 1 
Gatchel & Proctor 
(1976) 
USA - normal 36 - Self-Report 3 Speech anxiety 1 1 1 2 1 
Giardino et al. 
(2004) 
USA 63  
 
clinical 20 50 HADS 9 COPD 1 1 1 2 1 
Henriques et al. 
(2011) 
USA - normal 9 - STAI-T 20 Performance 
anxiety 
1 1 3 2 3 
Keeney (2009) USA 28 normal 7 100 STAI-T 5 Stress 
symptoms 
1 1 3 2 3 
Lee et al. (2015) Korea 27  
 
normal 5 20 STAI-T 4 Trait anxiety 1 1 1 2 1 
Mikosch et al. 
(2010)  
EU 66 clinical 106 50 STAI-S 1 CA 3 3 1 2 3 
Munafò et al. 
(2016) 
EU 50  normal 16 0 STAI-T 5 Stress 
symptoms 
1 1 1 2 1 
Nance (2015)  USA 37 clinical 13 100 BAI 10 BPD 1 1 2 2 1 
20 
Patron et al. 
(2013) 
EU 61 clinical 13 15 STAI-T 5 cardiac surgery 1 1 1 2 1 
Paul et al. (2012) India 21 normal 10 44.33 STAI-T 10 Trait anxiety 1 1 1 2 1 
Prinsloo et al. 
(2011) 
Africa 33 normal 9 0 STAI-S 1 Stress 
symptoms 
2 1 3 2 3 
Prinsloo et al. 
(2013) 
Africa 33 normal 9 0 STAI-S 1 Stress 
symptoms 
2 1 1 2 1 
Ratanasiripong et 
al. (2012) 
USA 19 normal 30 100 STAI-S 35 Stress 
symptoms  
1 1 1 2 1 
Reiner (2008) USA - clinical 19 50 STAI-T 21 sympathetic 
over-arousal 
1 1 3 2 3 
Sherlin et al. 
(2009)  
USA 33 normal 43 48.8 STAI-S 1 Stress 
symptoms 
1 1 3 2 3 
Sutarto et al.  
(2012) 
Indonesia 36 normal 19 100 DASS 5 anxiety 1 1 3 2 3 
Tan et al. (2011) USA 36  clinical 20 0 PCL-S 8 PTSD 1 1 1 2 1 
Thurber (2007) USA 23 normal 7 42.86 STAI-T 2 Performance 
anxiety 
3 1 3 2 3 
Wells et al. (2012) Australia 30  normal 14 52.17 STAI-S 1 performance 
anxiety 
2 1 3 2 3 
White (2008) USA 45 clinical 13 10 DAPS 50 Substance 
abuse 
3 1 3 2 3 
Zucker et al. 
(2009) 
USA - clinical 19 44.7 DAPS 20 PTSD 2 2 1 2 1 
van der Zwan et EU 27 normal 23 68 DASS 35 Stress 2 2 2 2 2 
21 
al. (2015) symptoms 
Note. Outcome measures: BPD, Borderline Personality Disorder;  COPD, chronic obstructive pulmonary disease;  CA, coronary angiography; PTSD, posttraumatic stress  disorder; 
Instrument: BAI, Becks Anxiety Inventory; HADS, Hospital Anxiety and Depression Scale; STAI-S, State-Trait Anxiety Inventory, State Version; STAI-T, State-Trait Anxiety 
Inventory, Trait Version; PCL-S, PTSD Checklist; SCL-90-R, Symptom Checklist 90 Revised; PSS, Perceived Stress Scale; DAPS, Detailed Assessment of Posttraumatic Stress; DSP, 
Derogatis Stress Profile; DASS, Depression Anxiety Stress Scale. Risk of study bias: R=Randomization, A=Allocation Concealment, I=Incomplete Data, S=Selective Outcome 
Reporting; unclear risk=1, low risk=2, high risk=3. 
 
Table 2. Within-group effect sizes of HRV Biofeedback  
Study (year) Outcome Hedges’ g Standard Error Variance Lower limit Upper limit Z-Value p-Value 
Beckham et al. (2013) STAI-S 0.24 0.20 0.04 -0.15 0.63 1.22 0.22 
Browne (2001) DSP 0.79 0.26 0.07 0.28 1.31 3.02 0.003 
Gatchel & Proctor (1976) Self-Report 0.59 0.18 0.03 0.24 0.93 3.31 0.001 
Giardino et al. (2004) HADS 0.17 0.17 0.03 -0.16 0.50 1.04 0.30 
Henriques et al. (2011) STAI-T 0.74 0.27 0.07 0.22 1.28 2.77 0.006 
Keeney (2009) STAI-T 0.28 0.26 0.07 -0.23 1.23 0.79 0.29 
Lee et al. (2015) STAI-T 2.44 0.66 0.44 1.15 3.74 3.70 0.001 
Mikosch et al. (2010) STAI-S 2.09 0.13 0.02 1.83 2.35 15.6 0.001 
Munafò et al. (2016) STAI-T 0.81 0.28 0.08 0.26 1.35 2.91 0.004 
Nance (2015) BAI 0.62 0.22 0.05 0.19 1.06 2.80 0.005 
Patron et al. (2013) STAI-T 0.05 0.20 0.04 -0.35 0.44 0.24 0.81 
Paul et al. (2012) STAI-T 3.09 0.58 0.34 1.95 24.23 5.33 0.001 
Prinsloo et al. (2011) STAI-S 1.19 0.32 0.10 0.57 1.82 3.73 0.001 
Prinsloo et al. (2013) STAI-S 1.19 0.32 0.10 0.57 1.82 3.73 0.001 
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Study (year) Outcome Hedges’ g Standard Error Variance Lower limit Upper limit Z-Value p-Value 
Ratanasiripong et al. (2012) STAI-S 0.50 0.15 0.02 0.22 0.79 3.44 0.001 
Reiner (2008) STAI-T 0.56 0.18 0.03 0.20 0.92 3.03 0.002 
Sherlin et al. (2009) STAI-S 1.19 0.15 0.02 0.89 1.49 7.78 0.001 
Sutarto et al. (2012) DASS 0.86 0.26 0.07 0.35 1.37 3.31 0.001 
Tan et al. (2011) PCL-S 0.94 0.20 0.04 0.54 1.33 4.63 0.001 
Thurber (2007) STAI-T 0.15 0.26 0.07 -0.35 0.66 0.58 0.56 
van der Zwan et al. (2015)  DASS 0.29 0.16 0.03 -0.02 0.60 1.81 0.07 
Wells et al. (2012) STAI-S 1.06 0.32 0.10 0.43 1.69 3.30 0.001 
White (2008) DAPS 0.36 0.21 0.04 -0.05 0.76 1.71 0.09 
Zucker et al. (2009) DAPS 1.08 0.22 0.05 0.65 1.51 4.96 0.001 
Average Effect Size 
 
0.81 0.13 0.02 0.55 1.06 6.23 0.001 
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Table 3. Between-group effect sizes of HRV Biofeedback  
Study Outcome Comparison 
condition 
Hedges’ g Standard 
error 
Variance Lower limit Upper 
limit 
Z-Value p-Value 
Browne (2001) DSP WL 1.32 0.48 0.23 0.39 2.26 2.78 0.01 
Lee et al. (2015) STAI-T WL 2.68 0.83 0.69 1.06 4.30 3.24 0.001 
Mikosch et al. (2010) STAI-S SC 1.67 0.16 0.03 1.36 1.98 10.49 0.001 
Munafò et al. (2016) STAI-T DR 0.08 0.35 0.12 -0.61 0.77 0.22 0.82 
Patron et al. (2013) STAI-T TAU -0.68 0.39 0.15 -0.08 1.45 -1.75 0.08 
Paul et al. (2012) STAI-T WL 3.21 0.66 0.44 1.91 4.51 4.84 0.001 
Prinsloo et al. (2013) STAI-S SB 0.23 0.45 0.20 -0.66 1.11 0.50 0.62 
Ratanasiripong et al. (2012) STAI-S WL 1.06 0.27 0.07 0.53 1.60 3.89 0.001 
Sherlin et al. (2009) STAI-S SB 0.87 0.32 0.10 0.24 1.49 2.73 0.01 
Tan et al. (2011) PCL-S TAU 1.06 0.40 0.16 0.28 1.85 2.65 0.01 
Thurber (2007) STAI-T WL -0.15 0.50 0.25 -1.14 0.83 -0.31 0.76 
Wells et al. (2012) STAI-S WL 0.56 0.37 0.14 -0.16 1.29 1.53 0.13 
Zucker et al. (2009) DAPS PMR 0.17 0.32 0.10 -0.45 0.79 0.53 0.59 
Average Effect Size     0.83 0.25 0.06 0.34 1.33 3.34 0.001 
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Note. Types of comparison conditions: SC, standard care; TAU, Treatment as usual; DR, daily record; SB, sham biofeedback; PMR, progressive muscle relaxation; WL, waitlist. 
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Figure 1. Flow diagram of study selection process 
	
  Articles initially identified 
after removing duplicates  
(n = 1,801) 
Studies selected for further 
screening (n = 232) 
Articles excluded (n = 1,569): reviews, 
surveys, resumes, book chapters, no 
HRV Biofeedback 
Studies (n = 188) excluded for the 
following reasons: No pre- post- 
intervention, HRV biofeedback 
combined with another active 
treatment, no measures of stress or 
anxiety, no adult sample 
Studies to be considered for 
inclusion in meta-analysis (n = 32) 
Studies included in the 
meta-analysis (n = 24) 
Studies (n = 8) excluded because 
of insufficient data 
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Figure 2: Funnel Plot of Standard Error by Hedges’ g 
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